Post by Allucent

The difference between a successful PK analysis and unusable data can come down to a few minutes. With the FDA recommending 12–18 blood samples per participant in many bioavailability studies to adequately characterize a drug's PK profile, optimizing your sampling schedule is critical for regulatory-quality data. In a recent blog, Allucent's clinical pharmacology experts explore: 🔸 How PK sampling strategies evolve from Phase I through Phase III 🔸 Common considerations when designing a sampling schedule 🔸 Best practices for balancing data quality, patient burden, and study efficiency 🔸 Why getting the timing right early can strengthen your entire development program Read the blog: https://lnkd.in/e3rcjswm #Allucent #BringingNewTherapiesToLight #ClinicalPharmacology #Pharmacokinetics #PKSampling